DKK141.10
0.07% today
Copenhagen, Apr 02, 04:59 pm CET
ISIN
DK0061802139
Symbol
ALK B
Sector
Industry

ALK-Abelló Stock price

DKK141.10
-9.80 6.49% 1M
-28.80 16.95% 6M
-18.00 11.31% YTD
+18.70 15.28% 1Y
-15.25 9.75% 3Y
+64.00 83.01% 5Y
+103.60 276.27% 10Y
Copenhagen, Closing price Wed, Apr 02 2025
+0.10 0.07%
ISIN
DK0061802139
Symbol
ALK B
Sector
Industry

Key metrics

Market capitalization DKK31.22b
Enterprise Value DKK31.82b
P/E (TTM) P/E ratio 38.29
EV/FCF (TTM) EV/FCF 33.38
EV/Sales (TTM) EV/Sales 5.75
P/S ratio (TTM) P/S ratio 5.64
P/B ratio (TTM) P/B ratio 5.81
Revenue growth (TTM) Revenue growth 14.78%
Revenue (TTM) Revenue DKK5.54b
EBIT (operating result TTM) EBIT DKK1.09b
Free Cash Flow (TTM) Free Cash Flow DKK953.00m
Cash position DKK589.00m
EPS (TTM) EPS DKK3.68
P/E forward 26.31
P/S forward 5.04
EV/Sales forward 5.14
Show more

Is ALK-Abelló a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

ALK-Abelló Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ALK-Abelló forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a ALK-Abelló forecast:

Buy
86%
Hold
14%

Financial data from ALK-Abelló

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5,537 5,537
15% 15%
100%
- Direct Costs 1,985 1,985
11% 11%
36%
3,552 3,552
17% 17%
64%
- Selling and Administrative Expenses 1,661 1,661
10% 10%
30%
- Research and Development Expense 531 531
14% 14%
10%
1,360 1,360
50% 50%
25%
- Depreciation and Amortization 272 272
11% 11%
5%
EBIT (Operating Income) EBIT 1,088 1,088
64% 64%
20%
Net Profit 815 815
68% 68%
15%

In millions DKK.

Don't miss a Thing! We will send you all news about ALK-Abelló directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Peter Halling
Employees 2,753
Founded 1923
Website www.alk.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today